You searched for "regeneration"
Risk of pulled-in-two syndrome
Congenital fibrosis of the extraocular muscles (CFEOM) is along the risk factors for pulled-in-two syndrome (PITS). The aim of this study was to report six cases and discuss prevention and clinical management strategies. The author’s six cases represented an incidence...
Ahmed and Baerveldt glaucoma drainage implant outcomes
This study reports the surgical outcomes of both the Ahmed (AGV) and Baerveldt (BGI) glaucoma drainage implants in a cohort of patients with primary congenital glaucoma over a long follow-up in a single tertiary centre. This was a retrospective study...All eyes on the future symposium hailed a great success
Leading providers in the eye healthcare sector, Optegra Eye Health Care and ZEISS, have successfully hosted their annual CPD-accredited symposium, ‘All Eyes on the Future’, bringing together experts from across the ophthalmic sector. The symposium welcomed 90 attendees, including optometrists,...A look into the IOL space
Advances in the design and performance of intraocular lenses (IOLs) continue to be driven by demand for better outcomes, presbyopia correction and spectacle independence, alongside a better understanding of the dynamics of the crystalline lens, newer theories of accommodation and...The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD
Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...Discussing treatment modalities for bilateral wet AMD
A 65-year-old lady with bilateral wet AMD and vision of 6/24 comes with an internet search about current therapies. How do you explain the various treatment modalities available? There are two NICE approved treatments for wet age-related macular degeneration (AMD)....Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...Pathophysiology of diabetic macular oedema: why combination therapy may be better
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...Conference Report: RCOphth 2025
This year’s Royal College of Ophthalmologists Annual Congress in Liverpool brought together eyecare professionals from across the country and beyond for four days of thought-provoking content, collaborative discussion and exciting glimpses into the future of ophthalmology. The opening day was...Sharing best practice and landmark evidence in glaucoma care
Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...
The willingness of patients to participate in an eye donation registry for research
This paper explores the willingness of ophthalmic patients to donate their eyes post-mortem for research purposes. A total of 300 German patients with a median age of 70 years (range 19-95) completed the standardised questionnaire; 45.3% were female and the...
